Add like
Add dislike
Add to saved papers

Univariate and Multivariate Determination of Dapagliflozin and Saxagliptin in bulk and Dosage Form.

BACKGROUND: Dapagliflozin is a sodium glucose cotransporter-II inhibitor while Saxagliptin is a dipeptidyl peptidase-4 inhibitor. Both are used to manage Type II diabetes mellitus.

OBJECTIVE: The aim of this work is to develop four simple, accurate and precise UV-spectrophotometric methods, three univariate and one multivariate, were developed for the estimation of dapagliflozin and saxagliptin in their pure and marketed dosage forms.

METHOD: Method (A) is based on the ratio difference method; Method (B) is ratio subtraction with constant multiplication; while Method (C) is second derivative method and Method (D) is Partial least square.

RESULTS: The calibration curves for dapagliflozin and saxagliptin were linear within the concentration range of 2.50-50.0 μg/mL and 5.0-60.0 μg/mL, respectively. The specificity of the proposed methods was studied by analyzing different laboratory prepared mixtures and their combined pharmaceutical dosage form. According to the ICH guidelines, the three proposed methods were validated regarding the accuracy, precision and specificity. Method (D) is Partial least square that was employed for the determination of the same mixture in wavelength range of 205-300 nm. A statistical comparison was performed between the results of the proposed methods and those of a reported spectrophotometric method and there was not any statistically significant difference detected at 95% confidence limit regarding both precision and accuracy.

CONCLUSION: Four accurate, specific, and precise UV-spectrophotometric methods for dapagliflozin and saxagliptin testing and estimation were successfully utilized and validated.

HIGHLIGHTS: The examined methods are simple and do not involve sophisticated and expensive instruments and could be effectively employed in quality control laboratories for routine examination of the investigated drugs in their pure powdered or combined pharmaceutical formulations.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app